Objectives Despite the therapeutic benefits of disease‐modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA), concerns remain about their safety in patients with malignancy. Among patients with RA, we evaluated DMARD treatment patterns after lung cancer diagnosis and their association with survival. Methods We conducted a retrospective cohort study using the Veterans Affairs (VA) Corporate Data Warehouse (2002–2022). Among patients with RA, incident lung cancers were identified from VA Oncology data. Information on comorbidities, smoking history, cancer stage at diagnosis, and histology were collected. DMARD exposure (none, conventional synthetic DMARDs [csDMARDs] only, and biologic or targeted synthetic DMARDs [b/tsDMARDs] (with or without csDMARDs)) were assessed at landmark points, during the first 3‐months and 12‐months, after cancer diagnosis. Associations between DMARD class and mortality were estimated using Cox proportional hazards models adjusted with energy balancing weights to balance demographic, RA‐related, comorbidity, and cancer‐related covariates across exposure groups. Results Among 1,651 patients with RA and lung cancer, 1,334 survived beyond 3 months and were included in the primary landmark analysis. DMARD exposure groups included no DMARD use in 498 patients (37.3%), csDMARD use in 643 (48.2%), and b/ts/combination DMARD use in 193 (14.5%). In adjusted analyses, neither csDMARDs nor b/ts/combination DMARDs were significantly associated with all‐cause mortality or lung cancer–specific mortality at 3 years. Similar associations were observed in the 12‐month landmark analysis. Conclusions In U.S. Veterans with RA and lung cancer, DMARD use during the first year following cancer diagnosis was not associated with an increased 3‐year mortality.